Crowdonomics
DNALabs Canada Inc.

Reg A+ · Equity · Sep 2022

ClosedReg A+Equity
via DALMORE GROUP LLC · last checked Aug 16, 2026
Raised
$84.1K / $1M max
8% of ceiling
Investors
—
—
Estimated pre-money
$76.9M
—

Financials disclosed in this offering

FY2021 · hover for source
$442K
−$169K
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$441,716
Cost of goods sold
$205,863
Gross margin
53%
Net income
-$169,041
Balance sheet
Cash
$347,527
Accounts receivable
$50,535
Total assets
$529,300
Long-term debt
$38,386
Total liabilities
$265,203
Other
Headcount
5

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Oct 5, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Sep 26, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$76.9M
Price / share$9.00
Shares offered111,111

Estimated, not stated: $9.00 × 8,549,076 securities outstanding.

Offering details

Target—
Max$999,999
Min investment—
OpenedSep 15, 2022
Deadline—
ClosedApr 16, 2024
Days active579

Links & provenance

Source: SEC EDGAR
0001946688-22-000001
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.